Michel Afargan

Company: Starget Pharma

Job title: CTO

Seminars:

Maximising Radiopharmaceutical Development Through In-silico Modelling 2:45 pm

Outlining proprietary in-silico model Identifying optimal targeting approaches to be implemented Assessing isotope and chelator selectionRead more

day: P&T Track PM

Expanding Radiopharmaceutical Targeting Mechanisms with Novel Moieties to Harness Enhanced Specificity, Efficacy & Safety 11:00 am

The development of novel targeting moieties for radiopharmaceuticals has seen significant advancements, particularly in the context of targeting cancer cells and supporting tissues. These novel moieties include small peptides, cyclic peptides, bispecifics and nanobodies, each offering unique advantages in terms of specificity, stability, and pharmacokinetics. Uncovering the latest understandings and developments across novel targeting approaches,…Read more

day: Workshop B

Panel Discussion: Phase 0 for Radiopharmaceuticals: Benefits & Risks 12:00 pm

Uncovering the rationale behind conducting these preliminary studies Exploring the pharmacokinetic and pharmacodynamic data it can provide Considerations for initiating a phase 0 trialRead more

day: P&T Track AM